Treatment of Gastrointestinal Luminal Tuberculosis in Multidrug-Resistant Tuberculosis

When gastrointestinal luminal tuberculosis occurs in the setting of multidrug-resistant tuberculosis (MDR-TB), standard first-line TB regimens are insufficient. The presence of MDR-TB defines both the drug selection and the phasing of treatment.

Clinical Scenario

The patient has multidrug-resistant tuberculosis (MDR-TB) with gastrointestinal luminal involvement. MDR-TB continues to be a public health issue and a health security threat, and its presence fundamentally shapes the therapeutic strategy for GI-TB.

Treatment Approach (partial overview)

Management follows the WHO shorter MDR-TB regimen — a structured combination of an injectable agent alongside multiple oral medicines, delivered in two sequential phases. Transition between phases is guided by a key microbiological milestone.

Full drug combinations, phase durations, monitoring criteria, and adaptation rules are available in the complete protocol →

Key Treatment Goal

Achieving a negative sputum smear at the end of month 4. This milestone determines whether the regimen advances to the intensive phase or the initial phase is extended. Smear status at this point drives the phase decision.

Instant Access to Structured Evidence-Based Regimens

References

Multidrug-resistant TB (MDR-TB) continues to be a public health issue and a health security threat.
Kanamycin (an injectable agent), moxifloxacin, prothionamide, clofazimine, isoniazid, pyrazinamide and ethambutol, given together in an initial phase of 4 months (with the option of extending to 6 months if the patient is still positive on a sputum smear at the end of month 4).
Followed by an intensive phase of 5 months of treatment with four of the medicines (moxifloxacin, clofazimine, pyrazinamide, and ethambutol).
Medicines are taken once per day, all days of the week.
If the intensive phase is prolonged, the injectable agent is only given three times a week after the fourth month.

View source ↗